摘要
程序性死亡蛋白1(PD-1)及其配体(PD-L1)已经被证明在逃避机体的免疫系统中发挥重要的作用.近年来,PD-1/PD-L1阻断在很多恶性肿瘤中显示出较为明显的临床效果,这些恶性肿瘤包括恶性黑色素瘤、肾细胞癌、经典霍奇金淋巴瘤、非小细胞肺癌等. PD-1/PD-L1信息通路可能成为恶性肿瘤患者免疫治疗的新靶点.但目前免疫治疗在恶性骨肿瘤中的研究较少,PD-1/PD-L1在其中的临床研究进展仍有待阐明.文章分析了肿瘤免疫PD-1/PD-L1信号通路及作用机制,探讨了目前常用PD-1/PD-L1单抗在恶性骨肿瘤中的应用前景,以期为中国开展基于PD-1/PD-L1信号通路的恶性骨肿瘤治疗提供理论依据.
Programmed death receptor 1 (PD-1) and its ligand PD-L1 have been shown to play an important role in evading the immune system. In recent years, PD-1/PD-L1 blockade has shown significant clinical effects in many malignancies, including malignant melanoma, renal cell carcinoma, classic Hodgkin lymphoma, non-small cell lung cancer and so on. PD-1/PD-L1 signaling pathway has become a new target of immunotherapy in patients with malignant tumors. However, there are few researches on immunotherapy in malignant bone tumors, and the progress of clinical research on PD-1/PD-L1 remains to be elucidated. This review started from the mechanism of PD-1/PD-L1 signaling in tumor immunity, and analyzed the application prospect of PD-1/PD-L1 antibodies in malignant bone tumors. We hope to provide a theoretical basis for the treatment of malignant bone tumors based on PD-1/PD-L1 signaling pathway in China.
作者
黄海峰
朱华
杨先腾
郭晓轶
李姗姗
谢泉
田晓滨
杨志
Huang Haifeng;Zhu Hua;Yang Xianteng;Guo Xiaoyi;Li Shanshan;Xie Quan;Tian Xiaobin;Yang Zhi(Department of Orthopaedics, Guizhou Provincial People′s Hospital, Guiyang 550002, China;Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China;Department of Anesthesiology, Guizhou Provincial People′s Hospital, Guiyang 550002, China;College of Big Data and Information Engineering, Guizhou University, Guiyang 550025, China;Clinical Medical College of Guizhou Medical University, Guiyang 550025, China)
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2019年第6期410-414,共5页
Chinese Journal of Oncology
基金
国家自然科学基金(81560356、81571705、81671733)
北京市自然科学基金(7171002)
贵州省科学技术基金([2015]2089、[2019]1201)
贵州省卫生计生委科学技术基金(gzwjkj2018-1-040).
关键词
程序性死亡蛋白1
程序性死亡蛋白配体1
骨肿瘤
Programmed cell death protein 1, PD-1
Programmed cell death-Ligand 1, PD-L1
Bone neoplasms
